We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pediatrix Medical's Q2 Earnings Beat on Strong Patient Volumes
Read MoreHide Full Article
Key Takeaways
MD's Q2 adjusted EPS of 53 cents beat estimates by 26.2% and rose 55.9% year over year.
Lower operating costs and improved patient acuity supported a 26.6% rise in adjusted EBITDA.
MD raised 2025 adjusted EBITDA and net income guidance on stronger operating performance.
Shares of Pediatrix Medical Group, Inc. (MD - Free Report) have gained 12.1% since it reported second-quarter 2025 results on Aug. 5. The quarterly results were aided by higher patient volumes, improved patient acuity and favorable collections, along with a sharp decline in operating expenses. However, the upside was partly offset by a drop in net revenues resulting from the adverse impact of practice dispositions.
Pediatrix Medical reported second-quarter 2025 adjusted earnings per share (EPS) of 53 cents, which outpaced the Zacks Consensus Estimate by 26.2%. The bottom line surged 55.9% year over year.
Net revenues tumbled 7% year over year to $468.8 million. Nevertheless, the top line beat the consensus mark by 0.4%.
Pediatrix Medical Group, Inc. Price, Consensus and EPS Surprise
Same-unit revenues advanced 6.4% year over year, which came higher than our growth estimate of 1.1%. Same-unit revenues, attributable to patient volume, rose 2.9% year over year in the quarter under review.
Same-unit revenues from net reimbursement-related factors grew 3.5% year over year on the back of improved patient acuity in its hospital-based practices, favorable collection activity and higher administrative fees from hospital partners. The metric beat our growth estimate of 0.3%.
Total operating expenses of $409 million decreased 38.2% year over year and came lower than our estimate of $414.9 million. The year-over-year decline resulted from lower practice salaries and benefits, practice supplies and other operating expenses, general and administrative expenses, and transformational and restructuring-related costs.
Practice salaries and benefits of Pediatrix Medical came in at $323.5 million, which fell 9.6% year over year due to the impact of practice dispositions. Interest expenses decreased 11.4% year over year to $9.1 million, lower than our estimate of $9.5 million.
Net income totaled $39.3 million against the prior-year quarter’s loss of $153 million. Adjusted EBITDA rose 26.6% year over year to $73.2 million, which surpassed our estimate of $59.4 million.
MD’s Financial Update (as of June 30, 2025)
Pediatrix Medical exited the second quarter with cash and cash equivalents of $224.7 million, which slipped 2.3% from the 2024-end level. There were no outstanding borrowings on its revolving credit facility at the quarter-end.
Total assets of $2.1 billion dipped 2.4% from the figure at 2024-end.
Total debt, including finance leases, net, amounted to $607.5 million, down 1.6% from the figure as of Dec. 31, 2024.
Total shareholders’ equity of $833.8 million improved 9% from the 2024-end level.
MD generated net cash from operations of $19.7 million in the first half of 2025 against $18.3 million of net cash used in operations in the prior-year comparable period.
Share Repurchase Update for MD
Pediatrix Medical bought back common shares for $1.8 million in the first half of 2025. It had a leftover capacity of $1.1 million under its $500 million repurchase program (approved in August 2018) as of June 30, 2025.
MD’s 2025 View Revised
Management now projects adjusted EBITDA within $245-$255 million, up from the prior view of $220-$240 million.
Net income is estimated to be between $126.02 million and $133.32 million for 2025, higher than the earlier guidance of $106.21-$120.81 million.
Interest expenses are currently forecasted at $36.7 million for 2025. Income tax expenses are expected to be in the range of $46.61-$49.31 million.
Depreciation and amortization expenses are now estimated to be $22.9 million. Transformational and restructuring-related expenses are expected to $12.8 million at present.
Of the Medical sector players that have reported second-quarter 2025 results so far, the bottom-line results of Tenet Healthcare Corporation (THC - Free Report) , HCA Healthcare, Inc. (HCA - Free Report) and Edwards Lifesciences Corporation (EW - Free Report) beat the respective Zacks Consensus Estimate.
Tenet Healthcare reported second-quarter 2025 adjusted EPS of $4.02, which surpassed the Zacks Consensus Estimate by 41.6%. The bottom line soared 74% year over year. Net operating revenues advanced 3.2% year over year to $5.3 billion. The top line beat the consensus mark by 2.4%. Adjusted net income of $369 million climbed 63.3% year over year in the quarter under review. Adjusted EBITDA improved 18.6% year over year to $1.1 billion.
The Hospital Operations and Services segment recorded net operating revenues of $4 billion, which inched up 0.9% year over year. Adjusted EBITDA climbed 25.1% year over year to $623 million. Adjusted EBITDA margin of 15.6% improved 300 bps year over year. The Ambulatory Care segment’s net operating revenues rose 11.3% year over year to $1.3 billion. Adjusted EBITDA was $498 million, which advanced 11.4% year over year.
HCA Healthcare’s second-quarter 2025 adjusted EPS of $6.84 surpassed the Zacks Consensus Estimate by 10.5%. The bottom line improved 24.4% year over year. Revenues were $18.6 billion, which advanced 6.4% year over year. The top line beat the consensus mark by 0.7%. Same-facility equivalent admissions grew 1.7% year over year in the second quarter, while same-facility admissions increased 1.8% year over year.
Same-facility revenue per equivalent admission advanced 4% year over year. Same-facility inpatient surgeries dipped 0.3% year over year. Same-facility outpatient surgeries slipped 0.6% year over year. Additionally, same-facility emergency room visits inched up 1.3% year over year in the quarter under review. Adjusted EBITDA improved 8.4% year over year to $3.8 billion, which beat our estimate of $3.6 billion. HCA Healthcare operated 191 hospitals and roughly 2,500 ambulatory sites of care across 20 states and the United Kingdom as of June 30, 2025.
Edwards Lifesciences reported second-quarter 2025 adjusted EPS of 67 cents, which surpassed the Zacks Consensus Estimate by 8.1%. The figure increased 8.1% from the year-ago quarter’s level. Sales totaled $1.53 billion, up 11.7% year over year. The metric surpassed the Zacks Consensus Estimate by 2.7%. Global sales in the Transcatheter Aortic Valve Replacement product group amounted to $1.10 billion, up 8.9% year over year or 7.8% at constant currency (CER).
In Transcatheter Mitral and Tricuspid Therapies, sales totaled $134.5 million, up 61.9% from the prior-year figure on a reported basis (up 57.1% at CER). The Surgical Structural Heart segment delivered sales of $267 million, up 7.7% from the year-ago level on a reported basis and 6.8% at CER. The gross profit was $1.19 billion, up 8.6% year over year. The gross margin contracted 236 bps to 77.5% due to a 25% increase in the cost of sales. The operating margin contracted 62 bps to 26.7%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Pediatrix Medical's Q2 Earnings Beat on Strong Patient Volumes
Key Takeaways
Shares of Pediatrix Medical Group, Inc. (MD - Free Report) have gained 12.1% since it reported second-quarter 2025 results on Aug. 5. The quarterly results were aided by higher patient volumes, improved patient acuity and favorable collections, along with a sharp decline in operating expenses. However, the upside was partly offset by a drop in net revenues resulting from the adverse impact of practice dispositions.
Pediatrix Medical reported second-quarter 2025 adjusted earnings per share (EPS) of 53 cents, which outpaced the Zacks Consensus Estimate by 26.2%. The bottom line surged 55.9% year over year.
Net revenues tumbled 7% year over year to $468.8 million. Nevertheless, the top line beat the consensus mark by 0.4%.
Pediatrix Medical Group, Inc. Price, Consensus and EPS Surprise
Pediatrix Medical Group, Inc. price-consensus-eps-surprise-chart | Pediatrix Medical Group, Inc. Quote
MD’s Q2 Update
Same-unit revenues advanced 6.4% year over year, which came higher than our growth estimate of 1.1%. Same-unit revenues, attributable to patient volume, rose 2.9% year over year in the quarter under review.
Same-unit revenues from net reimbursement-related factors grew 3.5% year over year on the back of improved patient acuity in its hospital-based practices, favorable collection activity and higher administrative fees from hospital partners. The metric beat our growth estimate of 0.3%.
Total operating expenses of $409 million decreased 38.2% year over year and came lower than our estimate of $414.9 million. The year-over-year decline resulted from lower practice salaries and benefits, practice supplies and other operating expenses, general and administrative expenses, and transformational and restructuring-related costs.
Practice salaries and benefits of Pediatrix Medical came in at $323.5 million, which fell 9.6% year over year due to the impact of practice dispositions. Interest expenses decreased 11.4% year over year to $9.1 million, lower than our estimate of $9.5 million.
Net income totaled $39.3 million against the prior-year quarter’s loss of $153 million. Adjusted EBITDA rose 26.6% year over year to $73.2 million, which surpassed our estimate of $59.4 million.
MD’s Financial Update (as of June 30, 2025)
Pediatrix Medical exited the second quarter with cash and cash equivalents of $224.7 million, which slipped 2.3% from the 2024-end level. There were no outstanding borrowings on its revolving credit facility at the quarter-end.
Total assets of $2.1 billion dipped 2.4% from the figure at 2024-end.
Total debt, including finance leases, net, amounted to $607.5 million, down 1.6% from the figure as of Dec. 31, 2024.
Total shareholders’ equity of $833.8 million improved 9% from the 2024-end level.
MD generated net cash from operations of $19.7 million in the first half of 2025 against $18.3 million of net cash used in operations in the prior-year comparable period.
Share Repurchase Update for MD
Pediatrix Medical bought back common shares for $1.8 million in the first half of 2025. It had a leftover capacity of $1.1 million under its $500 million repurchase program (approved in August 2018) as of June 30, 2025.
MD’s 2025 View Revised
Management now projects adjusted EBITDA within $245-$255 million, up from the prior view of $220-$240 million.
Net income is estimated to be between $126.02 million and $133.32 million for 2025, higher than the earlier guidance of $106.21-$120.81 million.
Interest expenses are currently forecasted at $36.7 million for 2025. Income tax expenses are expected to be in the range of $46.61-$49.31 million.
Depreciation and amortization expenses are now estimated to be $22.9 million. Transformational and restructuring-related expenses are expected to $12.8 million at present.
MD’s Zacks Rank
Pediatrix Medical currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Of the Medical sector players that have reported second-quarter 2025 results so far, the bottom-line results of Tenet Healthcare Corporation (THC - Free Report) , HCA Healthcare, Inc. (HCA - Free Report) and Edwards Lifesciences Corporation (EW - Free Report) beat the respective Zacks Consensus Estimate.
Tenet Healthcare reported second-quarter 2025 adjusted EPS of $4.02, which surpassed the Zacks Consensus Estimate by 41.6%. The bottom line soared 74% year over year. Net operating revenues advanced 3.2% year over year to $5.3 billion. The top line beat the consensus mark by 2.4%. Adjusted net income of $369 million climbed 63.3% year over year in the quarter under review. Adjusted EBITDA improved 18.6% year over year to $1.1 billion.
The Hospital Operations and Services segment recorded net operating revenues of $4 billion, which inched up 0.9% year over year. Adjusted EBITDA climbed 25.1% year over year to $623 million. Adjusted EBITDA margin of 15.6% improved 300 bps year over year. The Ambulatory Care segment’s net operating revenues rose 11.3% year over year to $1.3 billion. Adjusted EBITDA was $498 million, which advanced 11.4% year over year.
HCA Healthcare’s second-quarter 2025 adjusted EPS of $6.84 surpassed the Zacks Consensus Estimate by 10.5%. The bottom line improved 24.4% year over year. Revenues were $18.6 billion, which advanced 6.4% year over year. The top line beat the consensus mark by 0.7%. Same-facility equivalent admissions grew 1.7% year over year in the second quarter, while same-facility admissions increased 1.8% year over year.
Same-facility revenue per equivalent admission advanced 4% year over year. Same-facility inpatient surgeries dipped 0.3% year over year. Same-facility outpatient surgeries slipped 0.6% year over year. Additionally, same-facility emergency room visits inched up 1.3% year over year in the quarter under review. Adjusted EBITDA improved 8.4% year over year to $3.8 billion, which beat our estimate of $3.6 billion. HCA Healthcare operated 191 hospitals and roughly 2,500 ambulatory sites of care across 20 states and the United Kingdom as of June 30, 2025.
Edwards Lifesciences reported second-quarter 2025 adjusted EPS of 67 cents, which surpassed the Zacks Consensus Estimate by 8.1%. The figure increased 8.1% from the year-ago quarter’s level. Sales totaled $1.53 billion, up 11.7% year over year. The metric surpassed the Zacks Consensus Estimate by 2.7%. Global sales in the Transcatheter Aortic Valve Replacement product group amounted to $1.10 billion, up 8.9% year over year or 7.8% at constant currency (CER).
In Transcatheter Mitral and Tricuspid Therapies, sales totaled $134.5 million, up 61.9% from the prior-year figure on a reported basis (up 57.1% at CER). The Surgical Structural Heart segment delivered sales of $267 million, up 7.7% from the year-ago level on a reported basis and 6.8% at CER. The gross profit was $1.19 billion, up 8.6% year over year. The gross margin contracted 236 bps to 77.5% due to a 25% increase in the cost of sales. The operating margin contracted 62 bps to 26.7%.